Overview :
The Technology Development Board signed an agreement with Griva Healthcare on August 10, 2026, to commercialise GrivaVision, an indigenous AI-powered cervical cancer screening device. This portable digital colposcope uses proprietary hardware and AI-assisted software to detect pre-cancerous abnormalities. The device is now set for commercial-scale manufacturing.
GrivaVision
Think of GrivaVision as a smart microscope for cervical cancer screening. It combines high-definition optics, AI software, and portability to help doctors spot abnormalities earlier. Unlike traditional colposcopy (which requires bulky equipment), GrivaVision is portable and user-friendly.
The AI Advantage
The AI-assisted software acts like a second pair of expert eyes. It highlights potential pre-cancerous lesions, making it easier for gynaecologists to identify abnormalities during routine check-ups. This improves early detection rates, especially in resource-limited settings.
Indigenous Development
More than 50% of GrivaVision's components are sourced indigenously. This aligns with the Make in India initiative and reduces dependency on imports. The device also has Indian-patented hardware, protecting domestic innovation.
Regulatory and Quality Compliance
-
ISO 13485 International quality management standard for medical devices
-
CDSCO licence Manufacturing approval from India's drug regulator
-
Class B classification Low-to-moderate risk device
These certifications ensure safety and reliability.
Digital Health Integration
Compliance with Ayushman Bharat Digital Mission (ABDM) enables seamless integration with India's digital health ecosystem. This supports data sharing, patient records, and telemedicine applications.
WHO Compliance
The device aligns with WHO-approved Automated Visual Evaluation (AVE) standards, making it suitable for global health programmes.
Commercialisation Path
Moving from R&D in Visakhapatnam to commercial production in Kollam, Kerala, represents a crucial step in making this technology available at scale.
Exam-Focused Points :
-
Device GrivaVision—AI-powered portable digital colposcope for cervical cancer screening
-
Developer Visakhapatnam-based M/s Griva Healthcare Pvt. Ltd.
-
Technology AI-assisted software, Indian-patented hardware, advanced optics, HD camera, built-in display
-
Regulatory compliance Class B non-invasive medical device; ISO 13485 certified; CDSCO manufacturing licence
-
Manufacturing plan Moving from R&D (AIC-AMTZ, Visakhapatnam) to commercial plant (Kollam, Kerala)
-
Digital health integration Compliant with Ayushman Bharat Digital Mission (ABDM)
-
Indigenous content More than 50% components sourced indigenously
FAQs :
Q1: What is GrivaVision?
An AI-powered, portable digital colposcope for cervical cancer screening.
Q2: Who developed it?
Visakhapatnam-based Griva Healthcare Pvt. Ltd., with support from the Technology Development Board.
Q3: What is the significance of this device?
It is an indigenous, AI-driven screening tool that helps gynaecologists detect pre-cancerous abnormalities.
Q4: What are its regulatory standards?
Class B non-invasive device; ISO 13485 quality management; CDSCO licensed.
Q5: Where will it be manufactured?
A commercial-scale plant in Kollam, Kerala.